Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.COV2.S dose-ranging study in healthy adolescents
2020-005720-11Phase 2
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Solicited local and systemic adverse events after dose 1 and dose 2.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005720-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005720-11.